Radiopharmaceutical Therapy with [177Lu]Lu-DOTATATE in Refractory Meningiomas: Results from the French Multicenter MELUTE Cohort. (PubMed, J Nucl Med) - Oct 16, 2026 - "Meningioma WHO grade independently predicted PFS, whereas higher Karnofsky performance status and corticosteroid use were protective; worse OS was associated with higher baseline tumor growth rate and prior systemic therapy. MELUTE demonstrates promising efficacy and favorable safety of [177Lu]Lu-DOTATATE in refractory meningiomas with limited therapeutic options."
Journal • Brain Cancer • Meningioma • Oncology • Solid Tumor
|
|
Adrien Carle-Ortiz; Agathe Edet-Sanson; Anthime Flaus; Anthony Joncour; Antoine Verger; Aymeri Huchet; Betty Salgues; Caroline Boursier; Caroline Bund; Catherine Ansquer; Catherine Cheze-Le-Rest; Edouard Samarut; Elodie Vauleon; Elske Quak; Emeline Tabouret; Emmanuel Deshayes; Enora Vauléon; Eric Guedj; François Ducray; François Ghiringhelli; Gabriela Hossu; Gauthier Delaby; Georges Noël; Ghoufrane Tlili; Inna Dygai-Cochet; Jacques Darcourt; Jean-Sebastien Guillamo; Jeanne Riverain; Julien Boetto; Justine Attal; Laetitia Imbert; Lavinia Vija; Luc Taillandier; Marc Sanson; Marie Onno; Matthieu Peyre; Nicolas Garabedian; Pierre Meneret; Sarah Boughdad; Solène Querellou; Tatiana Horowitz; Thibault Fidani; Thomas Graillon; Timothée Zaragori; Vincent Bourbonne
|